Lanean...
PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence
Gastric adenocarcinoma is a leading cause of global cancer-related morbidity and mortality, and new therapeutic approaches are needed. Despite the improved outcomes with monoclonal antibodies targeting human epidermal growth factor receptor 2 and vascular endothelial growth factor receptor 2, durabl...
Gorde:
| Argitaratua izan da: | Gastrointest Cancer |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5533281/ https://ncbi.nlm.nih.gov/pubmed/28757801 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/GICTT.S113525 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|